EHL service area
Brain & Neurology
Topics on this page come from disease information published by EHL BIO and connect to assessment at the hospital in Korea.
Korean regenerative-medicine law
Korea provides a regulated advanced regenerative-medicine treatment pathway
Korea's amended law, effective 21 February 2025, allows designated advanced regenerative-medicine institutions to submit treatment plans for committee review and charge for treatment delivered under a plan found suitable.
The law does not automatically authorise every stem-cell type for every disease. Access depends on the institution's status, cell type, condition, a suitable reviewed plan and individual patient assessment.
Overview from EHL
EHL presents stem-cell research related to the neurological environment in Alzheimer's disease.
Conditions (1)
Why choose EHL
- EHL credentialEHL Cell Clinic designated as the first clinic-level advanced regenerative-medicine institutionEHL source
- EHL credentialHuman cell management business licence from Korea's MFDSEHL source
- EHL credentialEHL BIO GMP cell-manufacturing centreEHL source
- EHL credentialPatent for fat-harvesting and SVF separation kitEHL source
- EHL credentialRegenerative-medicine partnership with Gangnam Severance HospitalEHL source
- EHL credentialKorean Minister of Health and Welfare awardEHL source
- EHL credentialIR52 Jang Young-sil award for technology innovationEHL source
Service steps
- 1Send history and test results for consultation
- 2Individual physician assessment
- 3Cell collection at the hospital in Korea
- 4Culture and quality control in the GMP lab
- 5Administration under a reviewed plan
- 6Follow-up with the clinical team
What to prepare
- Treatment history and current medications
- Recent blood tests, imaging or physician reports
- The goals you want to discuss
- Passport and readiness to travel to Seoul
Suitability depends on physician assessment; results vary between individuals.